Angiotensin II receptor blocker attenuates stress pressor response in young adult African Americans.

What Was Tested

This randomized controlled trial looks at Angiotensin II.

African Americans (AAs) are susceptible to hypertension (HTN) and its associated organ damage leading to adverse cardiovascular (CV) outcomes.

Psychological stress is proposed to contribute to the development of HTN; however, the potential role of the renin-angiotensin system (RAS) in stress-related HTN in AAs is largely unknown.

Who Took Part

PubMed indexes the participants as teenagers, young adults and adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and crossover.

Because people in this Angiotensin II study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Angiotensin II, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Angiotensin II could be set against what happens without it.

Each person switched between Angiotensin II and the comparison at some point, usually with a gap in between.

What Was Measured

African Americans (AAs) are susceptible to hypertension (HTN) and its associated organ damage leading to adverse cardiovascular (CV) outcomes.

On the final day of each treatment, hemodynamic measures and urinary sodium excretion (UNaV) were collected before, during and after a 45 minute-mental stress.

The subject headings attached to it are Black or African American, Angiotensin Receptor Antagonists, Blood Pressure, Case-Control Studies, Hemodynamics, Hypertension and Irbesartan.

Author keywords: African Americans, angiotensin II and stress.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Angiotensin II.

The publication is from 2019 (Journal of clinical hypertension (Greenwich, Conn.)), a journal based in United States.

More context: the Angiotensin II compound page, all human trials.